Background: Patients with peripheral artery disease (PAD) fall under the category of a very high cardiovascular
risk. Although, consequent lipid lowering therapy (LLT) is advised, only sparse data on attained target level in PAD exists.
Objectives: We aimed to analyse contemporary guideline recommendations for LLT in symptomatic PAD patients.
Methods: monocentric, prospective, observational study involving 200 symptomatic PAD patients. Guideline target level
attainment and LLT were analysed between 2017 and 2019.
Results: Overall 78.5% of the patients were on statin therapy, mainly of high intensity with atorvastatin in 50% and
rosuvastatin in 33% of the cases. Average statin dosage adjusted for simvastatin was 55 mg/d. Low density lipoproteincholesterol (LDL-C) was <1.8 mmol/L in 53% and <1.4 mmol/L in 34% of the cases. Mean LDL-C levels were at 1.85 ±
0.88 mmol/L. We observed no difference in the treatment and the target level attainment of patients with a stable PAD
(intermittent claudication) or chronic critical PAD. However, patients with ≥1 vascular region affected (i.e. coronary and/or
cerebrovascular) were treated more intensively and had lower LDL-C levels than patients with PAD alone.
Conclusion: It appears that there is more awareness and improvement of previously documented undertreatment of LDL-C
levels in symptomatic PAD patients. Although statin treatment is initiated in the majority of patients, our findings call for a
continuously intensified LLT in symptomatic PAD patients.